AtriCure, Inc. $ATRC Shares Bought by Neuberger Berman Group LLC

Neuberger Berman Group LLC lifted its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC) by 0.3% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,189,739 shares of the medical device company’s stock after purchasing an additional 3,674 shares during the quarter. Neuberger Berman Group LLC’s holdings in AtriCure were worth $38,969,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in ATRC. Envestnet Asset Management Inc. boosted its stake in AtriCure by 22.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 56,656 shares of the medical device company’s stock worth $1,828,000 after buying an additional 10,570 shares during the last quarter. CWM LLC boosted its position in shares of AtriCure by 46.2% in the first quarter. CWM LLC now owns 2,818 shares of the medical device company’s stock worth $91,000 after acquiring an additional 891 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in AtriCure by 10.5% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,435 shares of the medical device company’s stock worth $466,000 after purchasing an additional 1,377 shares during the last quarter. Mackenzie Financial Corp raised its stake in AtriCure by 91.6% during the first quarter. Mackenzie Financial Corp now owns 29,143 shares of the medical device company’s stock worth $940,000 after purchasing an additional 13,929 shares during the period. Finally, XTX Topco Ltd acquired a new position in shares of AtriCure in the 1st quarter valued at $526,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of AtriCure in a research report on Wednesday, October 8th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research report on Thursday, October 30th. Canaccord Genuity Group raised their price target on shares of AtriCure from $53.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Finally, Wall Street Zen upgraded shares of AtriCure from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $52.22.

Insiders Place Their Bets

In related news, insider Justin J. Noznesky sold 5,166 shares of the stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $37.29, for a total value of $192,640.14. Following the sale, the insider owned 78,798 shares of the company’s stock, valued at $2,938,377.42. This trade represents a 6.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sven Wehrwein sold 4,967 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $38.00, for a total transaction of $188,746.00. Following the completion of the sale, the director owned 34,374 shares in the company, valued at $1,306,212. The trade was a 12.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 21,166 shares of company stock valued at $785,278 over the last three months. Company insiders own 3.50% of the company’s stock.

AtriCure Price Performance

Shares of ATRC stock opened at $36.03 on Friday. The firm has a fifty day moving average of $35.12 and a two-hundred day moving average of $34.24. The firm has a market cap of $1.79 billion, a P/E ratio of -59.06 and a beta of 1.56. AtriCure, Inc. has a 1-year low of $28.29 and a 1-year high of $43.11. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.94 and a quick ratio of 2.83.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Wednesday, October 29th. The medical device company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.10. The company had revenue of $134.27 million during the quarter, compared to analyst estimates of $131.25 million. AtriCure had a negative return on equity of 2.56% and a negative net margin of 5.55%.The business’s revenue was up 15.8% on a year-over-year basis. During the same quarter last year, the firm earned ($0.17) EPS. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. As a group, research analysts anticipate that AtriCure, Inc. will post -0.6 earnings per share for the current fiscal year.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.